{"filing":{"accession_number":"0001213900-26-080475","cik":"0001106644","ticker":"CPHI","company_name":"CHINA PHARMA HOLDINGS, INC.","form":"8-K","filing_date":"2026-07-22","report_date":null,"primary_document":"ea0298921-8k_china.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1106644/000121390026080475/ea0298921-8k_china.htm"},"events":[{"id":19692,"run_id":17718,"accession_number":"0001213900-26-080475","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"China Pharma entered into a securities purchase agreement and announced the pricing of a registered direct offering of 2.5 million shares of common stock at $2.00 per share, generating $5 million in gross proceeds. The offering includes investor participation rights in future financings and materially dilutes existing shareholders' ownership percentages.","company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","filing_date":"2026-07-22","form":"8-K","submitted_at":null,"items":[{"id":18861,"accession_number":"0001213900-26-080475","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"China Pharma entered into a securities purchase agreement to issue 2.5 million shares of common stock at $2.00 per share for $5 million in gross proceeds in a registered direct offering. This is a registered equity issuance that will dilute existing shareholders. The filing discloses material terms including the purchase price, share count, gross proceeds, and investor participation rights in future financings, all hallmarks of a dilutive equity capital raise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T21:26:46.420834+00:00","company_name":"","ticker":null,"filing_date":""},{"id":18862,"accession_number":"0001213900-26-080475","item_number":"8.01","item_title":"Other Events","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"China Pharma announced the pricing of a registered direct offering of 2.5 million shares at $2 per share, generating $5 million in gross proceeds. This is a registered equity issuance that dilutes existing shareholders. The offering is material to investors as it affects share count, ownership percentages, and the company's capital structure, and the press release explicitly discloses the pricing and terms of the offering.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T21:26:46.420834+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18861,"accession_number":"0001213900-26-080475","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"China Pharma entered into a securities purchase agreement to issue 2.5 million shares of common stock at $2.00 per share for $5 million in gross proceeds in a registered direct offering. This is a registered equity issuance that will dilute existing shareholders. The filing discloses material terms including the purchase price, share count, gross proceeds, and investor participation rights in future financings, all hallmarks of a dilutive equity capital raise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T21:26:46.420834+00:00","company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","filing_date":"2026-07-22"},{"id":18862,"accession_number":"0001213900-26-080475","item_number":"8.01","item_title":"Other Events","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"China Pharma announced the pricing of a registered direct offering of 2.5 million shares at $2 per share, generating $5 million in gross proceeds. This is a registered equity issuance that dilutes existing shareholders. The offering is material to investors as it affects share count, ownership percentages, and the company's capital structure, and the press release explicitly discloses the pricing and terms of the offering.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T21:26:46.420834+00:00","company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","filing_date":"2026-07-22"}]}